Caricamento...
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
ARAMIS is an international Phase III trial demonstrating the beneficial role of darolutamide, a novel anti-androgen that has been found to prolong metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. Darolutamide is a novel nonsteroidal androgen receptor antagonis...
Salvato in:
| Pubblicato in: | Asian J Androl |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer - Medknow
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6958984/ https://ncbi.nlm.nih.gov/pubmed/31249268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/aja.aja_52_19 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|